Investor Relations

Annual Meeting of Shareholders

  o Directions to CEL-SCI's Annual Meeting  
       

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations

  March 2015
Corporate Presentation

 
  February 2015
Exclusive Interview with Geert Kersten from the floor of the NYSE

 
  February 2015
Listen to CEO Participation in Ascendiant's Quarterly Management Discussion

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  MAY 1, 2015
NEW STORY CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  APRIL 13, 2015
NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial
  APRIL 1, 2015
NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  MARCH 3, 2015
NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  FEBRUARY 27, 2015
NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries
  FEBRUARY 20, 2015
NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today, Friday February 20 at 11 AM Eastern Time
  FEBRUARY 19, 2015
NEW STORY CEL-SCI's Phase III Head and Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the Trial
  FEBRUARY 18, 2015
NEW STORY CEL-SCI to Present At 3rd Annual Sachs Cancer Bio Partnering and Investment Forum
  FEBRUARY 11, 2015
NEW STORY The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  FEBRUARY 6, 2015
NEW STORY CEL-SCI Corporation Reports First Quarter 2015 Financial Results

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com